Biogen is developing lecanemab in partnership with Eisai, with all research, sales, and marketing costs to be shared equally between the two companies.

Source: https://seekingalpha.com/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings?source=feed_all_articles

FILE - This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi.

Source: https://ktar.com/story/5432748/why-a-new-alzheimers-drug-is-having-a-slow-us-debut/

Image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi.

Source: https://www.thehindu.com/sci-tech/health/alzheimers-drug-gets-fda-panels-backing-setting-the-stage-for-broader-use/article66953484.ece

That is why Eisai to price Leqembi at a wholesale acquisition cost (WAC) of $26,500 per year, well below the quantified societal value of $37,600 in the U.S. This is an estimated annual cost of 10mg/kg IV biweekly for an average US patient weight of 75kg.

Source: https://seekingalpha.com/article/4595343-eisai-potentially-best-bet-alzheimers-treatment-market?source=feed_all_articles